# reload+after+2024-01-22 17:45:07.430118
address1§P.O. Box 134
city§Malvern
state§PA
zip§19355
country§United States
phone§610 725 1500
website§https://www.galeratx.com
industry§Biotechnology
sector§Healthcare
longBusinessSummary§Galera Therapeutics, Inc., a clinical stage biopharmaceutical company, focuses on the development and commercialization of therapeutics for the transformation of radiotherapy in cancer. The company's lead product candidate is avasopasem manganese (GC4419), a small molecule dismutase mimetic, which has completed Phase III clinical trial for the treatment of radiotherapy induced severe oral mucositis in patients with head and neck cancer (HNC); in Phase IIa clinical trial for the treatment of radiotherapy-induced esophagitis in patients with lung cancer; and in Phase IIa clinical trial for patients with HNC undergoing standard-of-care radiotherapy. It is also developing GC4711, a dismutase mimetic product candidate, which is in Phase I/II clinical trial in combination with stereotactic body radiation therapy in patients with non-small cell lung cancer and locally advanced pancreatic cancer. The company was incorporated in 2012 and is based in Malvern, Pennsylvania.
fullTimeEmployees§31
companyOfficers§[{'maxAge': 1, 'name': 'Dr. J. Mel Sorensen M.D.', 'age': 66, 'title': 'CEO, President & Director', 'yearBorn': 1957, 'fiscalYear': 2022, 'totalPay': 908351, 'exercisedValue': 0, 'unexercisedValue': 0}, {'maxAge': 1, 'name': 'Mr. Christopher  Degnan', 'age': 43, 'title': 'Chief Financial Officer', 'yearBorn': 1980, 'fiscalYear': 2022, 'totalPay': 603518, 'exercisedValue': 0, 'unexercisedValue': 0}, {'maxAge': 1, 'name': 'Dr. Robert A. Beardsley M.B.A., Ph.D.', 'age': 62, 'title': 'Co-Founder & COO', 'yearBorn': 1961, 'fiscalYear': 2022, 'totalPay': 627520, 'exercisedValue': 0, 'unexercisedValue': 2811040}, {'maxAge': 1, 'name': 'Ms. Jennifer Evans Stacey Esq.', 'age': 58, 'title': 'Chief Legal & Compliance Officer and Secretary', 'yearBorn': 1965, 'fiscalYear': 2022, 'exercisedValue': 0, 'unexercisedValue': 0}, {'maxAge': 1, 'name': 'Ms. Andie  Collier', 'title': 'Chief Regulatory & Quality Affairs Officer', 'fiscalYear': 2022, 'exercisedValue': 0, 'unexercisedValue': 0}, {'maxAge': 1, 'name': 'Ms. Judy  Schnyder', 'title': 'Senior Vice President of Clinical Operations & Data Management', 'fiscalYear': 2022, 'exercisedValue': 0, 'unexercisedValue': 0}]
auditRisk§8
boardRisk§8
compensationRisk§7
shareHolderRightsRisk§7
overallRisk§8
governanceEpochDate§1704067200
compensationAsOfEpochDate§1672444800
maxAge§86400
priceHint§4
payoutRatio§0.0
beta§2.158
currency§USD
dateShortInterest§1702598400
forwardEps§-1.24
pegRatio§0.0
exchange§NGM
quoteType§EQUITY
shortName§Galera Therapeutics, Inc.
longName§Galera Therapeutics, Inc.
firstTradeDateEpochUtc§1573137000
timeZoneFullName§America/New_York
timeZoneShortName§EST
uuid§9ff241d9-e75a-35e9-b4be-f64d9dbab88e
gmtOffSetMilliseconds§-18000000
targetHighPrice§0.5
targetLowPrice§0.5
targetMeanPrice§0.5
targetMedianPrice§0.5
recommendationMean§3.0
recommendationKey§hold
numberOfAnalystOpinions§1
quickRatio§2.246
grossMargins§0.0
ebitdaMargins§0.0
trailingPegRatio§None
